A leucemia mieloide aguda (LMA) é um grupo de neoplasias decorrentes de células precursoras comprometidas com a diferenciação da linha celular mieloide. Todos eles são caracterizados pela expansão clonal de blastos mieloides. A LMA manifesta-se por febre, palidez, anemia, hemorragias e infecções recorrentes.
Introdução
O que você precisa saber de cara
A leucemia mieloide aguda (LMA) é um tipo de câncer do sangue que se origina pela multiplicação descontrolada de células anormais na medula óssea. A pessoa pode apresentar palidez intensa, cansaço devido à anemia, manchas roxas ou pequenos pontos de sangramento na pele, febre e infecções frequentes. O diagnóstico exige análise especializada das células da medula óssea e testes genéticos para definir as características da doença. No SUS, o tratamento é conduzido conforme a autonomia do serviço oncológico credenciado, existindo novas terapias incorporadas pela Conitec que ainda aguardam distribuição efetiva na rede pública.
A leucemia mieloide aguda (LMA) é um grupo de neoplasias decorrentes de células precursoras comprometidas com a diferenciação da linha celular mieloide. Todos eles são caracterizados pela expansão clonal de blastos mieloides. A LMA manifesta-se por febre, palidez, anemia, hemorragias e infecções recorrentes.
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 34 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 71 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
48 genes identificados com associação a esta condição.
Curadoria gene-doença
fontes oficiaisImmunodeficiency 21
An immunodeficiency disease characterized by profoundly decreased or absent monocytes, B-lymphocytes, natural killer lymphocytes, and circulating and tissue dendritic cells, with little or no effect on T-cell numbers. Clinical features of DCML include susceptibility to disseminated non-tuberculous mycobacterial infections, papillomavirus infections, opportunistic fungal infections, and pulmonary alveolar proteinosis. Bone marrow hypocellularity and dysplasia of myeloid, erythroid, and megakaryocytic lineages are present in most patients, as are karyotypic abnormalities, including monosomy 7 and trisomy 8. This syndrome links susceptibility to mycobacterial, viral, and fungal infections with malignancy and can be transmitted in an autosomal dominant pattern.
Nephronophthisis 7
An autosomal recessive disorder resulting in end-stage renal disease during childhood or adolescence. It is a progressive tubulo-interstitial kidney disorder histologically characterized by modifications of the tubules with thickening of the basement membrane, interstitial fibrosis and, in the advanced stages, medullary cysts.
D-2-hydroxyglutaric aciduria 2
A neurometabolic disorder causing developmental delay, epilepsy, hypotonia, and dysmorphic features. Both a mild and a severe phenotype exist. The severe phenotype is homogeneous and is characterized by early infantile-onset epileptic encephalopathy and cardiomyopathy. The mild phenotype has a more variable clinical presentation. Diagnosis is based on the presence of an excess of D-2-hydroxyglutaric acid in the urine.
Immunodeficiency, common variable, 14
A primary immunodeficiency resulting in recurrent sinopulmonary infections since early childhood, and characterized by hypogammaglobulinemia with undetectable IgG and IgA, poor response to vaccination, and decreased levels of switched memory B cells. CVID14 inheritance is autosomal dominant.
Pierpont syndrome
An autosomal dominant syndrome characterized by multiple congenital anomalies, global developmental delay, learning disability, palmar and plantar fat pads, and distinctive facial characteristics, especially when smiling.
Growth hormone insensitivity syndrome with immune dysregulation 1, autosomal recessive
An autosomal recessive form of growth hormone insensitivity syndrome, a congenital disease characterized by short stature, growth hormone deficiency in the presence of normal to elevated circulating concentrations of growth hormone, resistance to exogeneous growth hormone therapy, and recurrent infections. Most, but not all, patients have features of immune dysregulation.
X-linked dyserythropoietic anemia and thrombocytopenia
Disorder characterized by erythrocytes with abnormal size and shape, and paucity of platelets in peripheral blood. The bone marrow contains abundant and abnormally small megakaryocytes.
Microphthalmia, syndromic, 2
A very rare multiple congenital anomaly syndrome characterized by eye anomalies (congenital cataract, microphthalmia, or secondary glaucoma), facial abnormalities (long narrow face, high nasal bridge, pointed nose with cartilages separated at the tip, cleft palate, or submucous cleft palate), cardiac anomalies (atrial septal defect, ventricular septal defect, or floppy mitral valve) and dental abnormalities (canine radiculomegaly, delayed dentition, oligodontia, persistent primary teeth, or variable root length). Microphthalmia is a disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues (anophthalmia). In many cases, microphthalmia/anophthalmia occurs in association with syndromes that include non-ocular abnormalities.
Spinocerebellar ataxia 35
A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA35 patients commonly show upper limb involvement and torticollis. There is no cognitive impairment.
Wiedemann-Steiner syndrome
A syndrome characterized by hairy elbows (hypertrichosis cubiti), intellectual disability, a distinctive facial appearance, and short stature. Facial characteristics include long eyelashes, thick or arched eyebrows with a lateral flare, and downslanting and vertically narrow palpebral fissures.
Skeletal defects, genital hypoplasia, and impaired intellectual development
A disorder characterized by intellectual disability, craniofacial dysmorphism, microcephaly and short stature. Additional features include absence of the thumbs, hypoplasia of the radii and ulnae, additional vertebrae and ribs, retarded bone age and genital hypoplasia.
Hyper-IgE syndrome 1, autosomal dominant, with recurrent infections
A rare disorder of immunity and connective tissue characterized by immunodeficiency, chronic eosinophilia, distinctive coarse facial appearance, abnormal dentition, hyperextensibility of the joints, and bone fractures.
Bone marrow failure syndrome 2
An autosomal recessive disorder characterized by trilineage bone marrow failure, bone marrow hypocellularity, learning difficulties, and microcephaly. Insufficient hematopoiesis results in peripheral blood cytopenias, affecting myeloid, erythroid and megakaryocyte lines. Cutaneous features and increased chromosome breakage are not features.
Carney complex 1
CNC is a multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumors, and psammomatous melanotic schwannomas.
Tatton-Brown-Rahman syndrome
An overgrowth syndrome characterized by a distinctive facial appearance, tall stature and intellectual disability. Facial gestalt is characterized by a round face, heavy horizontal eyebrows and narrow palpebral fissures. Less common features include atrial septal defects, seizures, umbilical hernia, and scoliosis.
Piebald trait
Autosomal dominant genetic developmental abnormality of pigmentation characterized by congenital patches of white skin and hair that lack melanocytes.
Leukemia, acute myelogenous
A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.
Leukemia, acute myelogenous
A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.
Leukemia, acute myelogenous
A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.
Medicamentos aprovados (FDA)
4 medicamentos encontrados nos registros da FDA americana.
Variantes genéticas (ClinVar)
95 variantes patogênicas registradas no ClinVar.
Classificação de variantes (ClinVar)
Distribuição de 10.935 variantes classificadas pelo ClinVar.
Vias biológicas (Reactome)
304 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Leucemia mieloide aguda
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
Com ensaio aberto em 60 países. O ponto verde marca onde há vaga agora.
🟢 Recrutando agora
100 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
Publicações mais relevantes
Mostrando amostra de 200 publicações de um total de 29.162
Dynamic epigenetic regulation of BCLAF1 splicing in acute myeloid leukemia.
Na Leucemia Mieloide Aguda (LMA), este estudo identificou um desequilíbrio em duas formas da proteína BCLAF1: uma que promove o crescimento do câncer e outra que o suprime. A boa notícia é que o tratamento com "epidrogas" específicas pode restaurar esse balanço fisiológico, sugerindo um novo mecanismo para a LMA e abrindo caminho para o desenvolvimento de terapias inovadoras para pacientes.
🇧🇷 traduzidoImpact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.
Este estudo confirma que o índice de comorbidade para transplante de células hematopoiéticas (HCT-CI) continua sendo uma ferramenta crucial para prever riscos após o transplante em pacientes com leucemia mieloide aguda, mesmo quando a ciclosfamida pós-transplante (PTCY) é utilizada para prevenir a doença do enxerto contra o hospedeiro (DECH). A análise mostrou que um HCT-CI elevado ainda está associado a um maior risco de mortalidade não relacionada à recaída (NRM), e que a presença de comorbidades cardíacas é particularmente relevante e pode influenciar o prognóstico em pacientes que recebem PTCY. Isso sugere que, embora o HCT-CI seja válido, médicos e pacientes devem dar atenção especial às condições cardíacas ao usar PTCY.
🇧🇷 traduzidoIDH1 and IDH2 mutated myeloid neoplasms: mutational pattern, clonal hierarchy and the role in AML transformation.
Este estudo abrangente revelou que mutações nos genes *IDH1* e *IDH2*, importantes alvos para terapias direcionadas, estão presentes em 28% dos casos de Leucemia Mieloide Aguda (LMA) e em menor proporção em outras neoplasias mieloides. Crucialmente para pacientes e médicos, a mutação *IDH1* é frequentemente adquirida na transição de síndromes mielodisplásicas (SMD) ou leucemia mielomonocítica crônica (LMMC) para LMA, indicando seu papel na progressão da doença. Isso ressalta a importância de testes moleculares sequenciais para identificar essas mutações e guiar decisões de tratamento direcionado à medida que a doença evolui.
🇧🇷 traduzidoTrends in survival for adult patients with hematopoietic malignancies in Japan, 2000-14 (CONCORD-3).
Este estudo japonês (2000-2014) revelou uma melhora geral na sobrevida em 5 anos para pacientes adultos com cânceres hematológicos, incluindo a Leucemia Mieloide Aguda (LMA). As melhorias foram mais notáveis em pacientes mais jovens (15-54 anos) com doenças mieloides, enquanto a LMA especificamente teve um avanço moderado. Para pacientes, isso representa uma notícia encorajadora de progresso nos tratamentos; para os médicos, reforça a importância do monitoramento contínuo para refinar estratégias de controle e tratamento.
🇧🇷 traduzidoComparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics.
Para pacientes com leucemia mieloide aguda (LMA) de muito alto risco citogenético, este estudo mostra que a quimioterapia intensiva (IC) e a combinação de HMA com venetoclax (HMA+ven) oferecem taxas de remissão e sobrevida geral comparáveis, apesar do prognóstico geralmente desfavorável da doença. Essa equivalência de eficácia foi observada em diversas subpopulações cruciais, como pacientes com 60-75 anos e aqueles com mutação TP53. Portanto, HMA+ven representa uma opção de primeira linha razoável e igualmente eficaz para esses pacientes, especialmente os candidatos a transplante alogênico, oferecendo uma alternativa à quimioterapia intensiva.
🇧🇷 traduzidoPublicações recentes
A Rare Hybrid Presentation: Coexistence of Necrotizing and Histiocytoid Variants of Sweet Syndrome (SS) in a Patient With Acute Myeloid Leukemia (AML).
Acid ceramidase inhibition enhances BCL-2 targeting in venetoclax-resistant acute myeloid leukemia.
🥉 Relato de casoFunctions and mechanisms of circular RNAs in cancer stem cells and therapy resistance.
Neural network reveals platelet age from fluorescence microscopy images.
A report of novel inactivating missense mutations of BRCA1 detected in patients with acute myeloid leukemia.
📚 EuropePMC26.708 artigos no totalmostrando 197
The interaction between NPMc+ and Orai1 induces abnormal calcium influx to facilitate leukemogenesis.
The FEBS journalImpact of High Serum Lysozyme Activity on Renal Function and Survival Outcomes in Transplant-Eligible and Ineligible Acute Myeloid Leukemia.
Cancer medicinePotent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation.
Signal transduction and targeted therapyDynamic epigenetic regulation of BCLAF1 splicing in acute myeloid leukemia.
Cell death & diseaseLimited expression of B-cell maturation antigen in acute myeloid leukemia.
Journal for immunotherapy of cancerThe Regimen of Cladribine, Cytarabine, and Venetoclax (CAV) Induces Apoptosis in Acute Myeloid Leukemia Cells by Enhancing DNA Damage.
Journal of visualized experiments : JoVEEnhanced Remission and Survival Outcomes with Decitabine Plus Venetoclax in Additional Sex Comb Like 1 Mutated Acute Myeloid Leukemia.
Journal of visualized experiments : JoVE2g/m2 Ara-c induced more favorable outcome than 1g/m2 Ara-c in CLAG treatment for refractory or relapsed acute myeloid leukemia without increase toxicity: a multicenter propensity score matching analysis.
Annals of hematologyEnhancing cancer classification accuracy with a self-attention network using panel capture sequencing data.
Briefings in bioinformaticsDNA delivered by lipid nanoparticles induces CD8+ T cell-dependent antitumor responses and enhances anti-PD-L1 therapy.
JCI insightRadix Aconiti Lateralis Preparata and Coptidis Rhizoma mitigate the course of acute myeloid leukemia.
American journal of translational researchSimultaneous Determination of Venetoclax and Posaconazole in Human Plasma by UPLC-MS/MS: Application to Therapeutic Drug Monitoring in Acute Myeloid Leukemia Patients.
Drug design, development and therapyMetabolic pathways and chemotherapy resistance in acute myeloid leukemia (AML): Insights into Enoyl-CoA hydratase domain-containing protein 3 (ECHDC3) as a potential therapeutic target.
Cancer pathogenesis and therapyComplex Genetic Architecture in RASopathies: Constitutional PTPN11 and Mosaic RIT1 Pathogenic Variants Underlying Severe Noonan Syndrome With Adult-Onset Acute Myeloid Leukemia.
American journal of medical genetics. Part AMesothelin Promotes Acute Myeloid Leukemia Progression through LYN-dependent Signaling.
The Journal of biological chemistryLncRNA SNHG25 promotes proliferation, migration, and invasion of acute myeloid leukemia by competitively binding to miR-205-5p.
Clinical and experimental medicineA degradable multi-metal-chelating stealth nanoplatform for dual ferroptosis/cuproptosis-enhanced metalloimmunotherapy in leukemia.
Journal of nanobiotechnologyMRD as an early endpoint in myeloma and other hematologic malignancies: Implication for ongoing and future study designs.
Seminars in hematologyImpact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.
Transplantation and cellular therapyCladribine, low-dose cytarabine, and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: A global perspective.
Current research in translational medicineCirc-RERE promotes autophagy and immune escape in acute myeloid leukemia involving the miR-128-3p/ZEB1/PD-L1 axis.
Clinics (Sao Paulo, Brazil)T-cell receptor-engineered T cells (TCR-e T cells): A novel cellular therapy for hematopoietic malignancies?
Transplant immunologyMediastinal Germ Cell Tumors: Up Close and Personal.
JMIR cancerIDH1 and IDH2 mutated myeloid neoplasms: mutational pattern, clonal hierarchy and the role in AML transformation.
Blood advancesTrends in survival for adult patients with hematopoietic malignancies in Japan, 2000-14 (CONCORD-3).
Japanese journal of clinical oncologyDiscovery of 1,2,3,4-Tetrahydrochromeno[3,4-c]pyridin-5-one Derivatives as Novel MTHFD Inhibitors for the Treatment of Acute Myeloid Leukemia.
Journal of medicinal chemistryComparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics.
Blood neoplasiaDiscovery of potent bisindole-based pyrazolopyridine derivatives as topoisomerase inhibitors: DNA damage induction and synergistic antileukemic activity.
Frontiers in pharmacologyEfficacy and safety of a new cladribine-based conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with relapsed or refractory acute myeloid leukemia.
Frontiers in medicineEvaluation of Pirfenidone for the Treatment of Acute Respiratory Distress Syndrome: A Case Report.
Journal of biosciences and medicinesReal-world treatment patterns and clinical outcomes in patients with AML from 65 to 74 years unfit for first-line intensive chemotherapy in Japan.
International journal of hematologyOvercoming vascular niche-mediated TKI resistance in acute myeloid leukemia through miR-126 inhibition.
NPJ systems biology and applicationsInternational testing and refinement of AI algorithms predicting acute leukemia subtypes from routine laboratory data.
Nature communicationsTreatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study.
Clinical lymphoma, myeloma & leukemiaFlow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy.
American journal of hematology[Mutation characteristics and prognosis of patients with Fanconi anemia signaling pathway gene mutation myeloproliferative neoplasm].
Zhonghua yi xue za zhiCurrent landscape of mRNA therapeutics for acute myeloid leukemia.
Experimental hematologyA real-world analysis of the impact of azole antifungal prophylaxis on outcomes in patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based therapy.
Leukemia researchThe emerging role of plasmacytoid dendritic cell proliferation in acute myeloid leukemia.
Leukemia researchEmergence and continuous clonal evolution of a JAK2 exon 12-mutated myeloid clone after treatment for de novo acute myeloid leukemia.
Leukemia researchDiagnostic updates and research advances in AML-MR: Integrating molecular genetics and immune mechanisms.
Leukemia researchInvestigation of the expression and potential mechanistic role of BYSL in acute myeloid leukemia.
Clinical and experimental medicineCord blood versus matched related donor transplantation in AML not in remission: role of pre-engraftment immune reactions.
International journal of hematologyAptamer-targeted hybrid nanoparticles based on human exosomes and LXR agonist-loaded liposomes for enhanced anti-AML therapy.
Nucleosides, nucleotides & nucleic acidsTherapy-related acute myeloid leukemia following successful treatment of high-risk neuroblastoma in a pediatric patient: a case report and insights into late complications.
Frontiers in oncologyDiscovery of GBA-16-24 as a highly potent, selective ATR inhibitor for the treatment of FLT3-mutated acute myeloid leukemia.
RSC medicinal chemistryUnderrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry.
Open forum infectious diseasesDecoding the actionable potential of ribosome biogenesis in acute myeloid leukemia.
HaematologicaTargeting BMP and TAZ/TEAD mechanotransduction pathways impairs acute myeloid leukemia chemoresistance.
LeukemiaRelationship between Clostridioides Difficile Infections and Antimicrobial Use in Patients with Hematopoietic Diseases.
Internal medicine (Tokyo, Japan)Polθ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia.
Cell reports. MedicineGene Network Enrichment Analysis and Its Application to Explore Enriched Immune Disease Pathways for Gene Network of Acute Myeloid Leukemia Cell Lines.
Journal of computational biology : a journal of computational molecular cell biologyInhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML.
BloodDiscovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models.
BloodRandomized trial of GvHD Prophylaxis in Haploidentical PBSC Transplantation: ATG, PTCy, and Low-Dose Combination Therapy.
BloodDigital Surveillance After Allogeneic Hematopoietic Stem Cell Transplantation Guides Therapeutic Interventions to Reduce Non-Relapse Mortality.
European journal of haematologyConstruction and Validation of an N7-Methylguanosine-Related Prognostic Model for Acute Myeloid Leukemia.
Blood and lymphatic cancer : targets and therapyHealth Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2.
Blood and lymphatic cancer : targets and therapyEfficacy analysis of iptacopan in a patient with thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: a case report.
Frontiers in immunologyClinicopathological Spectrum of Acute Myeloid Leukemia and Treatment Outcomes in Kashmiri Population: A Prospective Study.
Journal of pharmacy & bioallied sciencesEffect of Somatic Variants Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Hematology/oncology and stem cell therapy[Research Progress of Megakaryocyte Morphology in the Prognosis of Primary Myelofibrosis--Review].
Zhongguo shi yan xue ye xue za zhi[NK Cell Immunotherapy for Acute Myeloid Leukemia: Recent Advances and the Immunomodulatory Role of Traditional Chinese Medicine--Review].
Zhongguo shi yan xue ye xue za zhi[Clinical Characteristics and Risk Factors of Human Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Acute Myeloid Leukemia].
Zhongguo shi yan xue ye xue za zhi[The Relationship between OPN, NLR and Chemotherapy Efficacy in Patients with Acute Myeloid Leukemia].
Zhongguo shi yan xue ye xue za zhi[Analysis of Clinical Characteristics and Prognosis in Patients with NCAM1-Positive Acute Myeloid Leukemia].
Zhongguo shi yan xue ye xue za zhi[Observation of the Therapeutic Effect of Venetoclax Combined with HEA Regimen on Acute Myeloid Leukemia Patients with KMT2A Gene Rearrangement].
Zhongguo shi yan xue ye xue za zhiEngineering CLL-1 CAR-NK cells via mRNA-LNP for potent antitumor activity and reversal of HLA-E-mediated resistance in acute myeloid leukemia.
Journal of experimental & clinical cancer research : CRCCAAT-enhancer binding protein delta functions as a tumor suppressor gene in acute myeloid leukemia.
Neoplasia (New York, N.Y.)Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosis.
Blood advancesMenin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia.
Current treatment options in oncologyA bispecific anti-fluorescein x anti-CD3 T-cell engager in combination with fluoresceinated adaptors enables lysis of AML cells.
Molecular cancer therapeuticsTwenty Years of Therapeutic Leukocytapheresis in Newly Diagnosed Acute Myeloid Leukemia: Insights From A Single Center.
Journal of clinical apheresisPaternal exposure to hydrocarbon solvents in the workplace and cancer risk in children and adolescents.
Journal of exposure science & environmental epidemiology[Efficacy and safety of venetoclax-cytarabine-homoharringtonine-based cytoreductive therapy before allogeneic hematopoietic stem cell transplantation in refractory/relapsed acute myeloid leukemia with RUNX1::RUNX1T1: a retrospective study].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi[Chinese guidelines for diagnosis and treatment of myelodysplastic neoplasms (2026)].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiDNA Methylation Stochasticity is Linked to Transcriptional Variability and Convergent Epigenetic Disruption Across Genetic Subtypes of Acute Myeloid Leukemia.
Cancer researchConstruction of a predictive model based on the risk of relapse after cytarabine consolidation therapy in AML patients.
The oncologistNR2F2/AGAP2 axis: regulating lipid synthesis to drive AML progression via AMPKα/ACC pathway.
Cellular oncology (Dordrecht, Netherlands)Absence of detectable bovine leukemia virus miRNAs in human cancer small RNA-seq datasets.
Microbiology spectrumOne size does not fit all: A comparative framework for optimizing ribonucleic acid transfection across acute myeloid leukemia cell lines.
Biology methods & protocolsALKBH5 facilitates acute myeloid leukemia development and immune escape via PD-L1 regulation.
Frontiers in oncologyCase Report: KMT2A amplification in two adult patients with B-cell acute lymphoblastic leukemia.
Frontiers in oncologyMicrotransplantation improves the outcome of older patients with newly diagnosed acute myeloid leukemia: a single-center study with long-term follow-up.
Frontiers in oncologyA phase I/II study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia: final analysis.
Therapeutic advances in hematologyEmphysematous Osteomyelitis: Three Rare Cases.
CureusProtein S-acylation dynamics provide metabolic plasticity to acute myeloid leukemia cells.
bioRxiv : the preprint server for biologySecondary T-Lymphoblastic Lymphoma With KMT2A::MAML2 Rearrangement Following Myeloid Sarcoma and RUNX1::RUNX1T1-Positive Acute Myeloid Leukemia.
Pediatric blood & cancerResearch Progress of Metabolic Reprogramming in Childhood Acute Leukemia.
Pediatric blood & cancerCLL-1: An emerging target for immunotherapy in acute myeloid leukemia.
Annals of hematologyClonal Dynamics of FLT3-ITD from Diagnosis to Relapse: Ultra-Sensitive Patient-Specific Monitoring by ddPCR.
International journal of molecular sciencesModulation of Leukemic Blasts into Dendritic Cells (DCleu) and Their Role in Predicting Survival in Patients with AML and MDS.
CancersAddition of Venetoclax to Azacitidine Did Not Improve Survival in Acute Myeloid Leukemia and Was Not Well Tolerated: Real World Experience.
CancersSingle-Cell Multi-Omics Identifies Measurable Residual Disease Targets Among Myelodysplasia- and Clonal Hematopoiesis-Related Genes in Acute Myeloid Leukemia.
CancersA Modified-Delphi Consensus on the Management of Patients with FLT3-Mutated AML.
CancersDNMT3B Controls Enhancer-Linked Chromatin and Cell Cycle Networks in Acute Myeloid Leukemia.
CancersClinical and hematological profile of patients with philadelphia-negative myeloproliferative neoplasms: First report from the Ecuadorian registry.
Hematology, transfusion and cell therapyMSLN expression predicts a high risk of EMD in AML by promoting cell adhesion and metastasis via interaction with MUC16.
Blood advancesDifferentiation Therapy in Acute Myeloid Leukemia: Advances in Phenotypic Screening and CRISPR-based Functional Genomics.
Acta haematologicaTransient Abnormal Myelopoiesis in a Non-Down Syndrome Infant With Subsequent Evolution to Acute Myeloid Leukemia.
Pediatric blood & cancerThe Analytical Performance and Inter-laboratory Standardization of Next-Generation Sequencing (NGS) Panels for Genetic Risk Stratification in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
CureusCharacterization of Acute Myeloid Leukemia With t(16;21) Translocation: Cytogenetic, Molecular, and Immunophenotypic Findings.
World journal of oncologyIntegrating Gene Expression With Recurrent Mutations Improves Age-Stratified Risk Prediction in Acute Myeloid Leukemia.
EJHaemIDH enzyme inhibition in cancer therapy: mechanisms, mutational insights, and effects of IDH inhibitors in glioma, acute myeloid leukemia and chondrosarcoma.
3 BiotechPost-Transplant Relapse in Acute Leukemia: Comparative Value of MRD and Chimerism.
Mediterranean journal of hematology and infectious diseasesProcedural State Anxiety in Pediatric Leukemia Patients Undergoing Bone Marrow Aspiration or Lumbar Puncture: A Cross-Sectional Study Using the Chinese Version of the State Anxiety Scale for Children.
Mediterranean journal of hematology and infectious diseasesPlasma Elastase Screening in Hematological Disease Reveals Its Potential as a Diagnostic and Prognostic Biomarker in Hematological Malignancies.
International journal of laboratory hematologyBPX-Net: biomarker-preserved explainable networks for disease diagnosis and prognosis.
BioData miningBudget Impact of Venetoclax for Newly Diagnosed Patients with Acute Myeloid Leukemia Aged ≥ 75 Years or with Comorbidities Precluding Intensive Chemotherapy in the United States.
Advances in therapyBeyond a prognostic model: Toward functional and clinical integration of chromatin remodeling genes in acute myeloid leukemia.
Journal of the Formosan Medical Association = Taiwan yi zhiProphylactic Levofloxacin Use in Oncology and Hematopoietic Stem Cell Transplants for Children Under 2 Years of Age.
Journal of pediatric hematology/oncologyImmune-metabolic plasticity in AML: Prognostic roles of aCTLs (activated Cytotoxic T Cells) and Kynurenine.
Current problems in cancerInfectious Complications in Children, Adolescents, and Young Adults Treated for Acute Leukemia and Lymphoblastic Lymphoma: A Single-Center Experience.
Journal of pediatric hematology/oncologyMDS/AML-associated DDX41 helicase facilitates homologous recombination repair by potentially resolving R-loops.
Nucleic acids researchNo increased risk of acute myeloid leukemia in adults with primary immune thrombocytopenia treated with thrombopoietin receptor agonists: a French nationwide population-based study.
HaematologicaThe PERK signaling pathway as a marker of the unfolded protein response in patients with acute myeloid leukemia.
Turkish journal of medical sciencesVisomitin as a differentiation-inducing therapeutic agent through SYK inhibition in AML.
Frontiers in pharmacologyOvercoming resistance to immune checkpoint inhibitor therapy in acute myeloid leukemia.
Frontiers in oncologyChidamide combined with decitabine, venetoclax, and low-dose cytarabine for relapsed/refractory acute myeloid leukemia: a single-center case series.
Frontiers in oncologySynergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia.
Blood neoplasiaIdentification of two novel TP53 mutations in secondary acute myeloid leukemia following multiple myeloma: a case report.
Blood science (Baltimore, Md.)Neuromyelitis Optica Spectrum Disorder in a Pediatric Patient Following Haploidentical Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.
Blood cell therapySingle-cell analysis of UNC13D-mediated immune and dedifferentiation heterogeneity in acute myeloid leukemia and development of a prognostic model.
Translational cancer researchLipid Droplet-Targeted Biomimetic Liposomes Potentiate Chemo-Ferroptosis Therapy in Leukemia.
Advanced materials (Deerfield Beach, Fla.)[Rapid determination of venetoclax in plasma by ultra performance liquid chromatography-tandem mass spectrometry].
Se pu = Chinese journal of chromatography[Simultaneous determination of selinexor, posaconazole, venetoclax, and voriconazole in human plasma using ultra-high performance liquid chromatography-tandem mass spectrometry].
Se pu = Chinese journal of chromatographyTowards evolutionary guided precision medicine of acute myeloid leukemia and Fanconi anemia associated bone marrow failure.
Stem cells translational medicineCo-Mutation of ASXL1 and KRAS Defines a Novel Ultra-Adverse-Risk Subtype of Acute Myeloid Leukemia in a Large-Scale Cohort.
Cancer medicineImmunophenotypic changes following menin inhibition in acute myeloid leukemia.
LeukemiaMidostaurin response in AML is shaped by a progenitor-like cell state selectively targeted by SMAC mimetics.
NPJ precision oncologyGain and Loss of FLT3 Mutations in Patients with Acute Myeloid Leukemia: A Noninterventional Cohort Study (CLEVO).
Oncology and therapyTP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a 3 comprehensive overview of targeted approaches.
Frontiers in oncologyAn extraction pipeline for analysis of hematopoietic stem cell transplantation data.
Bone marrow transplantationSuccessful allogeneic stem cell transplant in a patient with a left ventricular assist device: a novel case report.
Annals of hematologyA meta learning and task adaptive approach for drug target affinity prediction.
Nature communicationsIntegrated multi-target pharmacology of ginseng in acute myeloid leukemia through single-cell sequencing, molecular docking, network pharmacology, and in vitro experiments.
Discover oncologyComparative Genomics and Metabolomics of Domesticated, Pladienolide-Producing Streptomyces Bacteria.
Journal of natural productsChallenges of Dengue in Hematological Disease Patients: Descriptive Analysis From the DANGO Registry During the 2023-2024 Outbreak in Argentina.
Transplant infectious disease : an official journal of the Transplantation SocietyPharmacologic progress in higher-risk MDS: an uphill battle.
Expert opinion on pharmacotherapyBiomimetic Copper-Doped Nano-Aluminum Adjuvant Potentiates Therapy in Chemoresistant Acute Myeloid Leukemia.
Advanced healthcare materialsEffect of RAS Pathway Gene Mutations on Survival in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.
Cancer control : journal of the Moffitt Cancer CenterLong-term health-related quality of life and lifestyle behavior of patients with acute myeloid leukemia.
The oncologistMCT1 inhibition reprograms Treg metabolism via ABC transporters: implications for tumor immunity and the prognosis of acute myeloid leukemia patients.
European journal of medical researchReduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.
LeukemiaPreclinical advances and mechanistic insights of CAR-T therapy for acute myeloid leukemia: from target iteration to microenvironment regulation.
Annals of medicineUSP20, a Super-enhancer Regulated Gene, Promotes Acute Myeloid Leukemia Progression through CTNNB1 Deubiquitination.
International journal of biological sciencesClinical Integration of Menin Inhibitors in AML: Evolving Data and Therapeutic Perspectives.
Oncology researchTransient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy.
Immuno-oncology technologyThe clinical value of inflammatory factors in evaluating the prognosis of patients with acute myeloid leukemia.
Journal of medical biochemistryAssessing the contributions of noncoding RNAs in acute myeloid leukemia.
Blood neoplasiaHeterogeneous survival outcomes in molecularly defined acute myeloid leukemia with myelodysplasia-related changes.
Blood neoplasiaExtensive cerebral venous sinus thrombosis with hemorrhagic venous infarction as the initial presentation of acute myeloid leukemia: A case report.
Radiology case reportsOsmotic demyelination syndrome diagnosed by Magnetic Resonance Imaging in a child with tetraplegia: Case report.
Radiology case reportsPreliminary evidence for the integration of CNAs, CN-LOH and mutational profiles into the prognostic stratification of elderly patients with NPM1-mutated acute myeloid leukemia.
Oncology lettersPrognostic impact of myelodysplasia-related gene mutations in ELN-2022 favorable-risk acute myeloid leukemia subtypes.
Annals of medicineFusariosis in Patients With Hematologic Malignancies in the Era of Antifungal Prophylaxis.
Transplant infectious disease : an official journal of the Transplantation SocietyOptimization of the fragment binding to hinge region for a potent PIM kinase inhibitor based on N-pyridinyl amide scaffold.
European journal of medicinal chemistrySelinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
American journal of hematologySustained MYC Overexpression Drives Myeloid Differentiation Block and Acquisition of Leukemic Phenotypes.
Experimental hematologyValidating the European LeukemiaNet 2022 Guidelines in a Middle Eastern Acute Myeloid Leukemia Cohort: Correlation With Survival Outcomes and Comparison to ELN 2017.
Clinical lymphoma, myeloma & leukemiaDay 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Induction: The End of Story or Not Yet?
Technology in cancer research & treatmentThe role of macrophages and cytokines in the occurrence and development of MDS.
Clinical and experimental medicinescDIAGRAM: detecting chromatin compartments from individual single-cell Hi-C matrix without imputation or reference features.
Briefings in bioinformaticsInvasive Fusariosis Among Patients with Acute Leukemia: A 12-Year Single-Center Experience in a Middle-Income Country.
MycopathologiaSimultaneous quantification of venetoclax, busulfan and voriconazole in plasma by LC-MS/MS: Clinical applications in patients with acute myeloid leukemia.
Journal of pharmacological and toxicological methodsCytogenetic Profile of Newly Diagnosed Acute Myeloid Leukemia Patients: Insights from a Study at a Tertiary Care Centre in South India.
Asian Pacific journal of cancer prevention : APJCPThe prognostic impact of myeloid co-mutation burden in TP53-mutated AML/MDS after allogeneic stem cell transplantation: a multicenter retrospective analysis.
Annals of hematologyImproved overall survival in acute myeloid leukemia over the last 15 years.
Leukemia & lymphomaZiftomenib (Komzifti) for acute myeloid leukemia.
The Medical letter on drugs and therapeuticsLeukemia-targeting NK cell nanoengagers effectively promote robust NK activation and potent anti-acute myeloid leukemia response.
Journal of nanobiotechnologyCharacteristics of patients diagnosed for acute myeloid leukemia before and during the 2020 COVID-19 pandemic: the DATAML population-based cohort.
Scientific reportsGenomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia.
Blood cancer journalProphylactic Donor Lymphocyte Infusions in Pediatric Patients With High-Risk Hematological Malignancies.
European journal of haematologyLandscape of circular RNAs in acute myeloid leukemia and their clinical significance.
NPJ precision oncologyDesign, synthesis, and Lead optimization of novel Quinazoline-based FLT3 inhibitors with potent anti-acute myelogenous leukemia activity.
Bioorganic & medicinal chemistry lettersBeyond Endocarditis: Roth Spots in Acute Myeloid Leukemia.
The American journal of medicineNonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.
BloodValidation of ICC hierarchical classification in secondary AML.
Blood advancesChildhood cancer in Sweden during the COVID-19 pandemic: Temporal patterns in incidence and survival in a nationwide register-based cohort study.
PLoS medicineFASN inactivation-induced progranulin (GRN) expression promotes lysosome-dependent cell death to suppress leukemogenesis.
Cell reportsTrends in Long-Term Excess Mortality Risk and Survival Among Childhood and Adolescent Cancer Survivors in the United States.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyEvaluation of Drugs with Selective Inhibitors Targeting the Anti-Apoptotic Protein B-cell Lymphoma 2 (BCL-2) with Pro-Apoptotic and Antineoplastic Activities in Grade IV Glioblastoma.
Turkish neurosurgeryImpact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib.
HaematologicaAberrant fucosylation of extracellular vesicles remodels the vascular microenvironment and promotes chemoresistance in myelodysplastic syndromes and acute myeloid leukemia.
HaematologicaIntensive induction therapy with FLAG-idarubicin-venetoclax for fit older high-risk patients with acute myeloid leukemia.
HaematologicaEffect of pretransplant spleen volume on the prognosis of acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation.
Frontiers in immunologyCase Report: Sorafenib-induced rhabdomyolysis in a post-transplant patient with acute myeloid leukemia.
Frontiers in oncologyReal-World Analysis of Outcomes of Venetoclax+Azacitidine Versus 7+3 Induction in Acute Myeloid Leukemia.
EJHaemDiscovery of XYD270 as a Potent, Selective, and Orally Efficacious BRD9 PROTAC for Cancer Therapy.
Journal of medicinal chemistryConfounding factors in assessing the enriched expression of somatic mutant alleles in bulk tumor samples.
Genome research[Successful treatment of cardiac tamponade due to/pericardial infiltration with pericardial drainage and intrapericardial chemotherapy in a patient with acute myeloid leukemia].
[Rinsho ketsueki] The Japanese journal of clinical hematology[Venetoclax plus azacitidine as successful bridging therapy to second transplantation for post-transplant extramedullary relapse of acute myeloid leukemia].
[Rinsho ketsueki] The Japanese journal of clinical hematologyMeasurable residual disease detection in acute leukemia: Technological advances and clinical translation.
Leukemia researchDevelopment and characterization of anti-CXCR4 chimeric antigen receptor T cells.
Translational oncologyTwo new options for NPM1-mutated relapsed, refractory acute myeloid leukemia: Researchers are looking into whether revumenib or ziftomenib can be combined with first-line standard-of-care treatment options.
CancerThe oncogenic role of ecotropic viral integration site 1 in hematological malignancies: mechanisms of activation and leukemogenesis.
Frontiers in immunologyA Novel Synthetic Route for Lysine-Specific Demethylase 1-Targeting Compounds: CC-90011 and MS9117.
ChemMedChemAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Leucemia mieloide aguda.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Leucemia mieloide aguda e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
A condição é causada pela expansão clonal de blastos mieloides anormais na medula óssea. Mutações em genes como MLLT10, TERT e GATA2 estão catalogadas no desenvolvimento da enfermidade.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
10 publicações do grafo RarasNet (PubMed) · 8 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (s.d.). Leucemia mieloide aguda. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/leucemia-mieloide-aguda
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Leucemia mieloide aguda
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- Genética mendeliana
- fonte: OMIM
- Codificação WHO/SUS
- fonte: WHO ICD-10 / DATASUS
- CID-11 (futuro)
- fonte: WHO ICD-11
- NIH/GARD
- fonte: GARD (NIH)
- Indexação biomédica
- fonte: MeSH (NLM)
- Dado público estruturado
- fonte: Wikidata
- Medicamentos aprovados FDA
- fonte: FDA OpenFDA
- Reposicionamento
- fonte: Drug Repurposing Hub
- Ensaios clínicos
- fonte: ClinicalTrials.gov